Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27460712 | 0.86 | CYP19A1 (0.39) | TSHRSLC6A2SLC6A4SLC6A3MEN1 | |
| SCHEMBL9661892 | 0.79 | TSHR (0.60) | TSHRSLC6A2SLC6A4SLC6A3MEN1 | |
| SCHEMBL14413593 | 0.78 | ALDH1A1 (0.49) | TSHRSLC6A2SLC6A3MEN1KMT2A | |
| SCHEMBL11892291 | 0.78 | ALDH1A1 (0.49) | TSHRSLC6A2SLC6A3MEN1KMT2A | |
| SCHEMBL6244517 | 0.78 | TSHR (0.48) | TSHRSLC6A2SLC6A4SLC6A3MEN1 | |
| SCHEMBL751413 | 0.78 | ALDH1A1 (0.49) | TSHRSLC6A2SLC6A3MEN1KMT2A | |
| SCHEMBL13897184 | 0.78 | TSHR (0.48) | TSHRSLC6A2SLC6A4SLC6A3MEN1 | |
| SCHEMBL1195857 | 0.78 | TSHR (0.64) | TSHRSLC6A2SLC6A4SLC6A3MEN1 | |
| SCHEMBL733501 | 0.76 | CYP2C19 (0.58) | TSHRSLC6A2SLC6A3MEN1KMT2A | |
| SCHEMBL20569771 | 0.76 | CYP2C19 (0.35) | TSHRSLC6A2SLC6A3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1976509-B1 | PPAR MODULATORS | EVOLVA SA (CH) | 2014-12-17 | — | — | EP | claimed |
| US-20110178112-A1 | PPAR Modulators | EVOLVA SA (CH) | 2011-07-21 | — | — | US | claimed |
| EP-1976509-A2 | PPAR MODULATORS | Evolva SA (CH) | 2008-10-08 | — | — | EP | claimed |
| WO-2007138485-A2 | PPAR MODULATORS | EVOLVA SA (US) | 2007-12-06 | — | — | WO | claimed |
| EP-0266980-B1 | PHARMACEUTICAL COMPOSITIONS, COMPRISING A 2,4-DIPHENYL-1,3-DIOXANE DERIVATIVE AND AN INHIBITOR OF THROMBOXANE A2 SYNTHESIS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1992-10-28 | — | — | EP | claimed |
| EP-0201354-B1 | 2,4-DIPHENYL-1,3-DIOXANES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-09-19 | — | — | EP | claimed |
| US-4775685-A | THROMBOXANE A-2 ANTAGONISTS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1988-10-04 | — | — | US | claimed |
| EP-0266980-A2 | Pharmaceutical compositions, comprising a 2,4-diphenyl-1,3-dioxane derivative and an inhibitor of thromboxane A2 synthesis | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1988-05-11 | — | — | EP | claimed |
| EP-0201354-A2 | 2,4-Diphenyl-1,3-Dioxanes | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1986-11-12 | — | — | EP | claimed |
| US-20230414562-A1 | DUAL TNFR1 ANTAGONISTS AND TNFR2 AGONISTS FOR USE IN RENAL DISEASES | SERODUS ASA (NO) | 2023-12-28 | — | — | US | disclosed |
| US-20230414562-A1 | DUAL TNFR1 ANTAGONISTS AND TNFR2 AGONISTS FOR USE IN RENAL DISEASES | SERODUS ASA (NO) | 2023-12-28 | — | — | US | disclosed |
| CN-116568296-A | Dual TNFR1 antagonists and TNFR2 agonists for kidney disease | 赛罗多斯公司 | 2023-08-08 | — | — | CN | disclosed |
| EP-4000615-A1 | DUAL TNFR1 ANTAGONISTS AND TNFR2 AGONISTS FOR USE IN RENAL DISEASES | Serodus ASA (NO) | 2022-05-25 | — | — | EP | disclosed |
| EP-4000615-A1 | DUAL TNFR1 ANTAGONISTS AND TNFR2 AGONISTS FOR USE IN RENAL DISEASES | Serodus ASA (NO) | 2022-05-25 | — | — | EP | disclosed |
| US-4775685-A | THROMBOXANE A-2 ANTAGONISTS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1988-10-04 | — | — | US | disclosed |
| US-4775685-A | THROMBOXANE A-2 ANTAGONISTS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1988-10-04 | — | — | US | disclosed |
| EP-0266980-A2 | Pharmaceutical compositions, comprising a 2,4-diphenyl-1,3-dioxane derivative and an inhibitor of thromboxane A2 synthesis | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1988-05-11 | — | — | EP | disclosed |
| EP-0266980-A2 | Pharmaceutical compositions, comprising a 2,4-diphenyl-1,3-dioxane derivative and an inhibitor of thromboxane A2 synthesis | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1988-05-11 | — | — | EP | disclosed |
| EP-0201354-A2 | 2,4-Diphenyl-1,3-Dioxanes | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1986-11-12 | — | — | EP | disclosed |
| EP-0201354-A2 | 2,4-Diphenyl-1,3-Dioxanes | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1986-11-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178112-A1 | PPAR Modulators | PPARD, PPARG, PPARA | TSHR 422/4885SLC6A2 4462/4885SLC6A4 3333/4885 |
| US-20230414562-A1 | DUAL TNFR1 ANTAGONISTS AND TNFR2 AGONISTS FOR USE IN RENAL DISEASES | TNFRSF1A, TNFRSF9, TRAF2 | TSHR 128/4885SLC6A2 2380/4885SLC6A4 3378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.